Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
This study is testing a new approach for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), a type of blood cancer. It combines the anti-cancer drug Inotuzumab Ozogamicin (InO) with standard treatments like Dasatinib, Dexamethasone, Methotrexate, and Vincristine. The goal is to see if adding InO helps patients achieve a complete clinical remission (when the cancer is no longer detectable) more quickly. You may be able to join if you are 18 or older, have newly diagnosed Ph+ ALL, and your cancer cells show a specific marker called CD22. The study aims to enroll 25 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 25 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, complete clinical remission, is measured at 60 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Wendy Stock, MD · PRINCIPAL_INVESTIGATOR · University of Chicago
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants Who Enter Complete Clinical Remission at 60 Days as Defined by Criteria Set By The International Scale60 days
Complete clinical remission (when there are no signs of the disease) with a major molecular remission at 60 days as defined by participants who have a low ratio (less than or equal to .01%) of BCR-ABL1gene in their blood, according to criteria set by the International Scale for p210 BCR-ABL1.